Cargando…

Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling

Shikonin (SK) exerts neuroprotective effects; however, to date, its protective effect against chronic cerebral hypoperfusion- (CCH-) induced vascular dementia (VaD) has not been investigated. Therefore, the current study investigated whether SK could mitigate the cognitive deficits caused by CCH. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Yanqiu, Li, Zhe, Wang, Tianjun, Fan, Mingyue, Song, Jiaxi, Lv, Peiyuan, Jin, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205575/
https://www.ncbi.nlm.nih.gov/pubmed/34211568
http://dx.doi.org/10.1155/2021/5564246
_version_ 1783708530818154496
author Jia, Yanqiu
Li, Zhe
Wang, Tianjun
Fan, Mingyue
Song, Jiaxi
Lv, Peiyuan
Jin, Wei
author_facet Jia, Yanqiu
Li, Zhe
Wang, Tianjun
Fan, Mingyue
Song, Jiaxi
Lv, Peiyuan
Jin, Wei
author_sort Jia, Yanqiu
collection PubMed
description Shikonin (SK) exerts neuroprotective effects; however, to date, its protective effect against chronic cerebral hypoperfusion- (CCH-) induced vascular dementia (VaD) has not been investigated. Therefore, the current study investigated whether SK could mitigate the cognitive deficits caused by CCH. The effects of SK treatment on the PTEN/Akt/CREB/BDNF signaling pathway and apoptosis in hippocampal neurons were examined in a rat model of VaD established via bilateral common carotid artery occlusion (BCCAO). Fifty-two rats were randomly divided into 4 groups: sham, vehicle, SK-L (10 mg/kg SK per day), and SK-H (25 mg/kg SK per day). SK was regularly administered by gavage for 2 weeks. The results of the water maze test revealed that the escape latency in the vehicle group was significantly longer than that in the sham group, and rats in the vehicle group spent a smaller proportion of time in the target quadrant than those in the sham group. SK treatment reduced the escape latencies and increased the proportion of time spent in the target quadrant. Nissl staining showed morphological damage in the CA1 areas of the hippocampus in the vehicle group. SK treatment alleviated the injuries to hippocampal neurons. Western blot analysis showed higher p-PTEN and lower p-Akt, p-CREB, and BDNF expression in the vehicle group than in the sham group. SK administration reversed the upregulation of p-PTEN and the downregulation of p-Akt, p-CREB, and BDNF. The number of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling- (TUNEL-) positive cells in the hippocampal CA1 region of the vehicle group was significantly increased. Treatment with SK decreased the number of positive cells. Furthermore, as marker proteins of apoptosis, bcl-2 expression was decreased and bax expression was increased; thus, the ratio of bcl-2/bax was decreased in the vehicle group. SK treatment upregulated the expression of bcl-2 and downregulated the expression of bax, thereby elevating the bcl-2/bax ratio. Moreover, the aforementioned effects of SK were dose-dependent. The effect of 25 mg/kg per day was more obvious than that of 10 mg/kg per day. In conclusion, SK inhibited hippocampal neuronal apoptosis to protect against CCH-induced injury by regulating the PTEN/Akt/CREB/BDNF signaling pathway, consequently improving cognitive impairment.
format Online
Article
Text
id pubmed-8205575
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-82055752021-06-30 Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling Jia, Yanqiu Li, Zhe Wang, Tianjun Fan, Mingyue Song, Jiaxi Lv, Peiyuan Jin, Wei Evid Based Complement Alternat Med Research Article Shikonin (SK) exerts neuroprotective effects; however, to date, its protective effect against chronic cerebral hypoperfusion- (CCH-) induced vascular dementia (VaD) has not been investigated. Therefore, the current study investigated whether SK could mitigate the cognitive deficits caused by CCH. The effects of SK treatment on the PTEN/Akt/CREB/BDNF signaling pathway and apoptosis in hippocampal neurons were examined in a rat model of VaD established via bilateral common carotid artery occlusion (BCCAO). Fifty-two rats were randomly divided into 4 groups: sham, vehicle, SK-L (10 mg/kg SK per day), and SK-H (25 mg/kg SK per day). SK was regularly administered by gavage for 2 weeks. The results of the water maze test revealed that the escape latency in the vehicle group was significantly longer than that in the sham group, and rats in the vehicle group spent a smaller proportion of time in the target quadrant than those in the sham group. SK treatment reduced the escape latencies and increased the proportion of time spent in the target quadrant. Nissl staining showed morphological damage in the CA1 areas of the hippocampus in the vehicle group. SK treatment alleviated the injuries to hippocampal neurons. Western blot analysis showed higher p-PTEN and lower p-Akt, p-CREB, and BDNF expression in the vehicle group than in the sham group. SK administration reversed the upregulation of p-PTEN and the downregulation of p-Akt, p-CREB, and BDNF. The number of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling- (TUNEL-) positive cells in the hippocampal CA1 region of the vehicle group was significantly increased. Treatment with SK decreased the number of positive cells. Furthermore, as marker proteins of apoptosis, bcl-2 expression was decreased and bax expression was increased; thus, the ratio of bcl-2/bax was decreased in the vehicle group. SK treatment upregulated the expression of bcl-2 and downregulated the expression of bax, thereby elevating the bcl-2/bax ratio. Moreover, the aforementioned effects of SK were dose-dependent. The effect of 25 mg/kg per day was more obvious than that of 10 mg/kg per day. In conclusion, SK inhibited hippocampal neuronal apoptosis to protect against CCH-induced injury by regulating the PTEN/Akt/CREB/BDNF signaling pathway, consequently improving cognitive impairment. Hindawi 2021-06-07 /pmc/articles/PMC8205575/ /pubmed/34211568 http://dx.doi.org/10.1155/2021/5564246 Text en Copyright © 2021 Yanqiu Jia et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jia, Yanqiu
Li, Zhe
Wang, Tianjun
Fan, Mingyue
Song, Jiaxi
Lv, Peiyuan
Jin, Wei
Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
title Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
title_full Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
title_fullStr Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
title_full_unstemmed Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
title_short Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
title_sort shikonin attenuates chronic cerebral hypoperfusion-induced cognitive impairment by inhibiting apoptosis via pten/akt/creb/bdnf signaling
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205575/
https://www.ncbi.nlm.nih.gov/pubmed/34211568
http://dx.doi.org/10.1155/2021/5564246
work_keys_str_mv AT jiayanqiu shikoninattenuateschroniccerebralhypoperfusioninducedcognitiveimpairmentbyinhibitingapoptosisviaptenaktcrebbdnfsignaling
AT lizhe shikoninattenuateschroniccerebralhypoperfusioninducedcognitiveimpairmentbyinhibitingapoptosisviaptenaktcrebbdnfsignaling
AT wangtianjun shikoninattenuateschroniccerebralhypoperfusioninducedcognitiveimpairmentbyinhibitingapoptosisviaptenaktcrebbdnfsignaling
AT fanmingyue shikoninattenuateschroniccerebralhypoperfusioninducedcognitiveimpairmentbyinhibitingapoptosisviaptenaktcrebbdnfsignaling
AT songjiaxi shikoninattenuateschroniccerebralhypoperfusioninducedcognitiveimpairmentbyinhibitingapoptosisviaptenaktcrebbdnfsignaling
AT lvpeiyuan shikoninattenuateschroniccerebralhypoperfusioninducedcognitiveimpairmentbyinhibitingapoptosisviaptenaktcrebbdnfsignaling
AT jinwei shikoninattenuateschroniccerebralhypoperfusioninducedcognitiveimpairmentbyinhibitingapoptosisviaptenaktcrebbdnfsignaling